“A ‘US-first’ mindset, increasing share of US patients in clinical trials and building capability and talent, among other actions, will enable Novartis to achieve this objective,” the pharmaceutical company said in a Sept. 22 news release.
Switzerland-based Novartis pinned five therapeutics markets — cardiovascular, immunology, neuroscience, solid tumors and hematology — as a focus for future investments. Novartis is the No. 1 drug company in Germany and Japan, and plans to be in China’s top three list, according to the news release.
The company also gave a timeline for its recently announced spinoff drug business, Sandoz, which will be fully independent by the end of 2023.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
